Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OZTx-556
- Development stage
- Preclinical
- Lead developer
- Orizuru Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracardiac
01
Overview
OZTx-556 (also known as iCM) is an investigational regenerative cell therapy consisting of highly purified induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Developed by Orizuru Therapeutics through the T-CiRA collaboration between Kyoto University's Center for iPS Cell Research and Application (CiRA) and Takeda Pharmaceutical, it is designed for the treatment of severe chronic heart failure. The therapy works by transplanting these cardiomyocytes into the patient's heart to replenish lost cardiac cells and promote cardiac remuscularization, thereby restoring contractile function. The product is manufactured using a proprietary differentiation method and is designed for minimally invasive catheter administration. Preclinical studies in animal models, including rats and monkeys, have demonstrated significant improvements in left ventricular ejection fraction and stable long-term engraftment.
- Other names
- iPS cell-derived cardiomyocytesiCM Project
Beyond the preview
Go deeper on OZTx-556.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OZTx-556.